Jamjoom Pharma
جمجوم فارماTechnical Analysis & Signals
Jamjoom Pharma stock shows relative stability in the Saudi market with mixed signals.
Technical Analysis
The Relative Strength Index (RSI) is at 57.5, indicating that the stock may be in a neutral zone, while the MACD Hist suggests a slight decline in momentum. The sideways trend is likely to continue under these indicators.
Support & Resistance Levels
The support level is at 153.8 SAR, while resistance is at 157.03 SAR. The stock may test these levels if market fluctuations occur.
Volume Analysis
No trading volume data is provided, but trading volume is expected to impact price movement in the future. An increase in volume may indicate rising momentum.
Fundamental Factors
The price-to-earnings (P/E) ratio is 24.3, which may indicate a relatively high valuation. The dividend yield at 2.55% might attract some investors looking for steady income.
Risk Factors
Potential risks include general market volatility and macroeconomic impacts on stock performance. Any changes in government policies or economic conditions may affect the stock price.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Investors are advised to conduct their own research before making any investment decisions.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Jamjoom Pharma
4015Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 10.85B
- P/E Ratio
- 24.30
- P/B Ratio
- 6.30
- EPS (Earnings/Share)
- 6.38
Profitability
- Revenue
- 1.52B
- Net Income
- 474.98M
- Return on Equity (ROE)
- 0.00%
- Shares Outstanding
- 70.00M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 16.43M
- Debt/Equity
- 0.96
- Free Float %
- +34.5%
Dividends & Margins
- Dividend Yield
- +2.55%
- Dividend/Share
- 4.00
- Book Value
- 24.60
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
4 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2024 | 1.32B +19.8% | 356.52M +21.9% | 1.77B +7.1% | 2.09M -12.8% | 5.09 +21.8% |
| 2023 | 1.10B +20.1% | 292.40M +70.7% | 1.65B +17.5% | 2.40M -8.9% | 4.18 +70.6% |
| 2022 | 916.67M +24.6% | 171.31M +0.4% | 1.41B -1.7% | 2.64M +34.0% | 2.45 +0.4% |
| 2021 | 735.68M | 170.70M | 1.43B | 1.97M | 2.44 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Jamjoom Pharma used 75.1% of production capacity in 2025: CEO
Jamjoom Pharma provides SAR 31.8M corporate guarantee to Algerian JV
Jamjoom Pharma shareholders reject LTIP, buyback plan
Analysts’ views on Jamjoom Pharma Q4 2025 results, average TP
BSF Capital comments on Jamjoom Pharma Q4 results, sets TP
Jamjoom Pharma lowers revenue growth guidance for 2026, 2027
Firms likely to declare cash dividends in Feb. based on historical pattern
Rundown of Jamjoom Pharma's financials, operating segments in Q3 2025
News source: Argaam (argaam.com)
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-05-11
Risk Assessment
Risk Factors
Average True Range 3.3% of stock price
Trading volume near or above average
P/E ratio 24.3
Debt-to-equity ratio 0.96
ADX indicator at 29
Moderate risk factors with some sector pressures
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Jamjoom Pharma stock price today?
Jamjoom Pharma (4015) stock price today is 155.00 SAR, declining by -1.08% compared to the previous session close. The 52-week price range is between 123.13 SAR and 178.91 SAR.
2 What is Jamjoom Pharma stock valuation?
The automated analysis signal for Jamjoom Pharma is "Hold" with 65% confidence. The P/E ratio is 24.3. The P/B ratio is 6.30.
3 Is Jamjoom Pharma Shariah-compliant?
Yes, Jamjoom Pharma (4015) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Jamjoom Pharma dividend distributions?
Jamjoom Pharma has a dividend yield of 2.55%, with an estimated annual dividend of 4.00 SAR per share.
5 What is Jamjoom Pharma weekly performance?
Jamjoom Pharma performance over different time periods: weekly change -0.19%, monthly +2.24%, and year-to-date +9.27%. The stock is currently trading with a volume of 72,374 shares.
6 What is the target level for Jamjoom Pharma?
According to automated analysis for Jamjoom Pharma: Short-term target (1-2 weeks): 158.50 SAR. Support level: 153.80 SAR. Resistance level: 157.03 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.